key: cord-0952001-rvgbvy0g authors: Oh, Daniel; Haffey, Paul; Patel, Ankur; Gulati, Amitabh title: Intravenous Ketamine for Cancer Pain Management Including Flares During the COVID-19 Pandemic: A Retrospective Study date: 2021-06-04 journal: Pain Med DOI: 10.1093/pm/pnab163 sha: f3cbc3892efcc792f534650e7d7f4885b8d90a79 doc_id: 952001 cord_uid: rvgbvy0g OBJECTIVES: Cancer-related neuropathic pain (CNP) affects an increasing proportion of cancer patients given improved survival but remains difficult to treat. There are no studies on an extended intravenous (IV) ketamine protocol and its synergies with common neuropathy treatments to treat CNP. This study aims to (1) evaluate the safety and effectiveness of an IV ketamine protocol to treat refractory CNP and (2) uncover synergies between ketamine and common neuropathy treatments. METHODS: This is a single-center, retrospective review of 57 patients and 192 infusions with prospective follow-up on fourteen enrolled patients during the COVID-19 pandemic. RESULTS: The etiologies of CNP were 13 from tumor compression, 25 with chemotherapy-induced peripheral neuropathy, 13 from surgery, and 6 from radiation therapy. Overall, 42 out of 57 patients (73.7%) were responders. 71.8% of responders received >3 weeks of pain relief on their last infusion. Analysis of adjuvant treatments revealed the combination of serotonin-norepinephrine reuptake inhibitors (SNRI) and ketamine resulted in an increase in responders compared to non-responders (p < 0.01). Adverse events occurred in 32 of 192 infusions (16.7%). All side-effects self-resolved or resolved with intervention per the adverse events protocol. During the pandemic, all fourteen currently enrolled patients did not receive ketamine infusions. Thirteen of the fourteen patients returned to baseline pain with 61.5% increasing medications. All experienced worsened function, mobility, mood, and/or anorexia. CONCLUSION: IV ketamine may be a safe and effective adjuvant treatment for CNP, especially with SNRIs. Larger, prospective studies are warranted and should explore parameters to help prognosticate response to ketamine infusions. INTRODUCTION Advances in cancer treatments, including chemotherapy, surgery, and radiation therapy, have improved the survival of cancer patients. Unfortunately, these treatments may have serious painful side effects. Cancer-related neuropathic pain (CNP) affects up to 70% of all cancer patients. 1 CNP significantly contributes to loss of function and mobility, as well as worsened quality-of-life (QOL). 2, 3, 4 Additionally, patients with neuropathic pain are reported to have worse sleep, mood, cognition, as well as physical and social functioning. 5 The etiology of CNP is diverse and can be divided into tumor-related (i.e. direct tumor compression of a peripheral nerve) and treatment-related pain syndromes. 6 Treatment-related pain can be further categorized into chemotherapy-induced peripheral neuropathy (CIPN), postsurgical pain syndromes, and post-radiation pain and related neuritis. 1 It is estimated that 64% of CNP is due to direct tumor compression while 20% is from an adverse event after treatment. 1 The most common treatment-related pain is CIPN, which occurs in 90% of patients receiving neurotoxic chemotherapy. 7 Following initial insult to the nerve, pain fibers become hypersensitive and eventually transmit spontaneous pain signals to the brain. 1 CNP is characterized by acute flares on a chronic background, associated with paresthesia, dysesthesia, allodynia, hyperalgesia, and/or numbness. 7, 8 Treating CNP is challenging because of its chronicity which results from abnormally excitable neurons. 9 Traditional treatment modalities are limited to medications such as opioids, tricyclic antidepressants (TCA), serotonin-norepinephrine reuptake inhibitors (SNRI), gabapentinoids (gabapentin, pregabalin), other anticonvulsants, topical analgesics, and desensitization techniques, offering modest relief. 7 Furthermore, N-methyl D-aspartate (NMDA) antagonists in the form of oral, topical, intranasal, or parenteral ketamine are used to supplement existing treatments for refractory CNP. The NMDA channel is the principal receptor involved in central sensitization and windup phenomena which may lead to chronic pain. Ketamine's antagonistic effect on NMDA receptors is thought to confer benefit by reversing central sensitization and windup. 10 Ketamine has a unique combination of hypnotic, analgesic, and amnestic effects and is used for post-traumatic and peri-operative pain treatments. 10 However, these effects occur at anesthetic doses which are higher than sub-anesthetic doses used to treat chronic neuropathic pain or complex regional pain syndromes (CRPS). At sub-anesthetic doses, the main analgesic mechanism of action for ketamine is through non-competitive NMDA receptor antagonism. 11 Given that chronic pain and depression often occur together, there has been an increased interest in ketamine as an agent to treat chronic pain syndromes. 10 Specifically, several randomized controlled trials (RCTs) support the effectiveness of ketamine in CNP with positive results, however, lack robust statistical measures demonstrating significance. 10 Previous studies have assessed the effectiveness of intranasal, topical, and oral ketamine -but intravenous (IV) ketamine infusions appear to be the most promising route of administration. 10 IV ketamine has successfully treated non-oncologic neuropathic pain. 12 In the oncologic population, IV ketamine with morphine was shown to improve CNP. 13 However, another RCT could not confirm the effectiveness of a combination of IV ketamine and morphine to treat refractory cancer pain, including CNP. 14 These studies are limited by few contiguous infusions Academy of Pain Medicine Pain Medicine 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 and short-term follow-up with each patient receiving between one to three infusions with followup of pain reduction within hours to two days after infusion. A Cochrane Review by Bell et al. concluded there is insufficient evidence for the role of ketamine by any route to treat cancer pain, including CNP. 15 While IV ketamine is used to treat non-oncologic neuropathic pain, it has not been well-studied in the setting of CNP. This study explores the effectiveness and safety profile of an IV ketamine protocol for the treatment of CNP in patients with refractory pain control. This is the first longterm data set in the literature for cancer patients and will help establish a randomized control trial in this population. This is a single-centered, retrospective analysis on 57 consecutive patients between April 2018 and May 2020, diagnosed with neuropathic pain secondary to various malignancies and associated treatments, who underwent an IV ketamine infusion protocol. Patients' demographics, medical history, primary oncologic disease, presence of metastases, cancer treatments, etiology of neuropathic pain, symptomatology, pre-/post-infusion pain and function levels, patient satisfaction, adjuvant analgesics, adverse events, and interventions for adverse events were obtained via retrospective chart review. This study was approved via waiver for informed consent by Memorial Sloan Kettering Cancer The IV ketamine protocol consists of a series of four-hour infusion sessions. Prior to the start of each infusion, the patient's baseline parameters including pain via the numeric pain rating scale (NPRS), function, satisfaction, and use of analgesics were obtained by a registered nurse. All Academy of Pain Medicine Pain Medicine 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 female, pre-menopausal women had negative pregnancy tests prior to infusion. All patients were pre-medicated with oral ondansetron 4mg and oral lorazepam 0.5mg. The first ketamine infusion started at 10mg/hr, titrated by 5mg/hr, to a maximum of 25mg/hr as tolerated. All patients were eligible for a second and third infusion one week after the previous one, starting at 25mg/hr, titrated by 5mg/hr to a maximum of 40mg/hr. Responders continued with infusions roughly every 4 weeks and were titrated to a maximum dose of 70mg/hr as tolerated. Patients continued the infusions until they opted out due to undesirable side effects, unsatisfactory pain relief, or until death. Patients' body temperatures, blood pressures, pulse rates, and oxygen saturations were continuously monitored during each infusion session. If patients developed restlessness, they were given either oral lorazepam 0.5mg every four hours up to 2mg as needed or IV lorazepam 0.5mg once if unable to tolerate oral medications. If they developed nausea, they were given oral ondansetron 4mg every six hours as needed. If they developed other side effects such as tachycardia, hypertension, somnolence, headache, or hallucinations, physician evaluation led to administering of as needed medications, continuing with the infusion, or decreasing/discontinuing the infusion. If adverse events quickly self-resolved, no intervention was performed. Twenty-four hours after infusion, patients were contacted by the patient care team to assess pain parameters and adverse events. All patients followed up in clinic with our service as per standard care (on average 4 weeks after infusion) at which time pain improvement, adverse event, functional improvement, satisfaction of relief, current analgesics, and adverse events due to ketamine therapy were discussed and a decision was made to continue or cease the treatment. In this study, responders were defined as patients who reported ≥30% reduction in pain based on NPRS or positive subjective qualifiers, including but not limited to "good", "excellent", or "significant" pain relief, as well as functional improvements and/or reduction in adjuvant analgesics. Responders must have ≥24 hours of pain relief after their first infusion or ≥2 weeks of pain relief after their subsequent infusions to continue on protocol. Due to unforeseen and unfortunate circumstances surrounding the COVID-19 pandemic, there were fourteen patients on the IV ketamine protocol who could not proceed with monthly infusions. These patients were contacted in a prospective manner to assess for return to baseline pain, impact of pain, change in pain management, adverse events from last infusion, and length of response. Furthermore, all patients who have since received an infusion were tested for SARS-CoV-2 prior to infusion. If positive or symptoms of the virus, the infusion was not offered. The response rate to IV ketamine therapy was calculated for the total population and was also stratified by etiology of pain and analgesics. Differences between the responder and nonresponder groups were compared using the chi-squared test, with significance defined as p<0.05. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 A total of 57 patients with CNP were treated with the IV ketamine protocol (Table 1) . Patients who had underlying neuropathy or peripheral neuropathy, prior to the onset of their CNP, were excluded from the analysis. Each patient's pain was identified as secondary to either direct tumor compression (n=13), CIPN (n=25), post-surgical (n=13), or post-radiation (n = 6). The mean age was 52.23 years (SD 13.33). The most common primary cancer diagnosis was breast cancer (13 patients, 22.8%,) followed by nerve sheath tumors (7 patients, 12.3%). Eight out of 57 patients In total, 42 out of 57 patients were responders (73.7%), with 12 out of 42 (26.7%, p=0.0003) patients choosing to discontinue treatment due to unsatisfactory pain relief or undesirable adverse effects (Table 2) . Importantly, all responders had improvement in function and/or 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 mobility while on the IV ketamine protocol. Among the responders who received subsequent infusions, 7 out of 39 patients (17.9%) had pain relief under two weeks with their last infusion, 4 out of 39 patients (10.3%) had pain relief for 2 to 3 weeks, and 28 out of 39 patients (71.8%) had pain relief for over 3 weeks (p<0.01, Table 3 ). Nine out of 13 patients (69.2%) with neuropathic pain from tumor compression were responders, with three out of the nine patients (33.3%) deciding to forego future infusions due to unsatisfactory pain improvement or undesirable adverse events with subsequent infusions ( Table 2) . Twenty-one out of 25 patients with CIPN (84.0%, p=0.0007) responded, with four out of 25 patients (19.0%) deciding to forego more infusions due to the return of pain or adverse events as outlined above. Nine out of 13 patients (69.2%) with post-surgical neuropathic pain responded with four out of nine patients (44.4%) forgoing future infusions due to the return of pain or adverse events. Three out of six patients (50.0%) with post-radiation neuropathic pain responded and one of the three responders (33.3%) decided to forgo further treatments due to pain or adverse events. Thirty-nine out of 42 responders (92.9%) received two or more infusions. Twenty-eight out of 39 responders (71.8%) had pain relief for three or more weeks (Table 3) . Four out of 39 responders (10.3%) had pain relief for two to three weeks. Seven out of 39 responders (17.9%) had pain relief for under two weeks (p<0.01). This association was statistically significant in the CIPN group (p<0.01) with 17 out of 21 responders (81.0%) having over three weeks of pain relief. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Adjuvant Pain Treatments and Rate of Response All patients were stratified by whether they were on concurrent opioids, SNRIs, TCAs, or gabapentinoids in relation to response rates to IV ketamine (Table 4 ). There was no association with improved response rate when opioids (p=0.9299), TCA's (p=0.5681), or gabapentinoids (p=0.7985) were used in conjunction with IV ketamine. Specifically, no patients were on an anticonvulsant (other than gabapentinoids), thus this association was not explored. However, SNRIs such as duloxetine, with IV ketamine resulted in a statistically significant improvement in response rate to 91.7% from 35.6% in patients who did not use SNRIs while on IV ketamine (p=0.0017). There were 57 patients in this study who underwent 192 infusions (Table 5 ). In total, 25 out of 57 patients (43.9%) had an adverse event at some point during the duration of their IV ketamine protocol. However, 34 out of 192 infusions (17.7%) resulted in an adverse event. The most common adverse events were neurologic (7.8%) which includes headache, dizziness, and somnolence. This was followed by gastrointestinal adverse events (3.6%) consisting of nausea and vomiting. Cardiovascular events occurred in 2.1% of infusions, consisting of hypertension and tachycardia. 64.7% of adverse events self-resolved without intervention or change in infusion rate. 35.3% of cases resolved after the patient received as needed medications and/or the infusion rate was reduced or stopped. Importantly, no patients had life-threatening or serious adverse events requiring hospitalization. All adverse events resolved prior to discharge. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 There were 14 patients who were on the IV ketamine protocol when the decision was made to postpone all infusions during the COVID-19 pandemic ( Table 6 ). All patients were responders to multiple infusions prior to the pandemic with improvement of function, mobility, and mood with ketamine infusions. With the last infusion prior to the pandemic, 11 out of 14 patients (78.6%) continued to be responders with 9 out of 14 patients (64.3%) having over 3 weeks of pain relief. Notably, one patient in the post-surgical group had sustained relief for over three months without a return to baseline pain. The other thirteen patients had return of baseline pain. All patients subsequently reported decreased mobility, activities of daily living, mood, and/or anorexia. Eight 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 In this retrospective study of 57 patients, 42 patients (73.7%) were responders to the IV ketamine protocol, regardless of the etiology of CNP ( Table 2 ). The highest response rate was in patients suffering from CIPN with 21 out of 25 patients (84.0%) responding. Patients with neuropathic pain from direct tumor compression or post-surgical pain had 69.2% response rates. Postradiation pain resulted in 50.0% response rate, noting a sample size of six patients. This suggests that the extended IV ketamine protocol is effective to treat CNP of varying etiologies. The IV ketamine protocol and follow-up encounters in this study were administered over a longer timeframe than the IV ketamine programs that are currently reported. 3 An RCT of ketamine to treat CRPS found that patients received up to 11 weeks of statistically significant pain relief as compared to placebo. 16 Most patients in this study did not have recorded long-term follow-up data beyond 3 weeks of the last ketamine infusion. However, 71.8% of responders had over 3 weeks of pain relief with their last infusion. Although this difference in IV ketamine duration in the CRPS versus CNP population may be attributable to a lack of long-term data, it is possible that increased mechanical compression from tumor growth or continued cancer treatments have a cumulative effect on pain symptoms. Nevertheless, although the 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 duration of relief from ketamine infusions may be short, cancer patients may still benefit from ketamine infusions, for example as inpatients suffering from uncontrolled pain. It is notable that out of the 42 responders, 12 patients (26.7%) self-discontinued the IV ketamine protocol given subsequent infusions did not confer satisfactory pain relief or resulted in undesirable adverse events. In the CIPN group, this occurred only in four out of 25 patients 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 benefits on patient health and healthcare utilization. Interestingly, as ketamine may improve depressive symptoms in the cancer population, it is conceivable that ketamine may improve pain by improving depression. Prior studies have attempted to evaluate the utility of ketamine as a synergistic agent with opioids and other medications to treat CNP. 14, 18 In this investigation, 11 out of 12 patients (91.7%) using adjuvant SNRIs were responders, compared to 16 out of 45 patients (78.9%) not on adjuvant SNRIs who were deemed non-responders (p<0.01, Table 3 ). This difference was statistically significant in only the CIPN population (p<0.01), whereas in the tumor compression, post-surgical, and post-radiation CNP populations, statistical significance was not achieved. Importantly, there was no significant difference when comparing opioids versus non-opioids, TCAs versus non-TCAs, and gabapentinoids versus non-gabapentinoids. SNRIs such as duloxetine are commonly used to treat various neuropathic pain syndromes, and may secondarily treat anxiety and depression. Duloxetine inhibits a P450 liver enzyme, CYP2B6 which metabolizes ketamine. 19 Thus, by inhibiting CYP2B6, SNRIs could theoretically augment the effects of ketamine. 20, 21 In animal models, NMDA receptor blockade is thought to enhance the effect of duloxetine. 19 Interestingly, a Cochrane Review concludes that there is moderate quality evidence that duloxetine at higher doses (60mg to 120mg daily) is effective for treating peripheral neuropathy. 22 Additionally, a randomized, controlled trial by Smith et al. demonstrated a benefit for duloxetine in treating CIPN. 23 An enhanced effect of duloxetine may mimic higher doses. This study suggests the need for further investigation to evaluate the potential synergistic properties of SNRI medications and ketamine when treating CNP. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Notably, adjuvant opioids did not confer a statistically significant difference in response to IV ketamine. Some studies have demonstrated that clinically, ketamine enhances the effect of opioids. 17 Mouse models have suggested ketamine-mediated NMDA antagonism to potentiate the anti-nociceptive effects of mu-opioid agonists. 24 However, a Cochrane Review found low evidence for ketamine as an adjuvant to opioids for cancer pain treatment. 15 This study was consistent with this finding given that there was no difference in response rate between patients with adjuvant opioids versus no opioids (66.7% versus 79.2%, respectively). Of note, there were three patients who were not on any adjuvant medications after choosing to forego any other medications given lack of effectiveness and responded to the IV ketamine protocol. The different effects of adjuvant pain treatments or the absence of adjuvants with IV ketamine is particularly interesting given that ketamine antagonizes NMDA receptors and interacts with many other receptors. 25 By uncovering synergistic effects with certain adjuvants, IV ketamine has the potential to decrease medication burden and most significantly, opioid burden. More studies are warranted to confirm the utility of IV ketamine in decreasing pain and opioid burden as well as increasing function, mobility, sleep, pain relief satisfaction, and ultimately QOL. Several studies with a limited number of infusions concluded that IV ketamine is a relatively safe medication. 13, 14 Our study is congruent with the current literature with 17.7% of infusions resulting in an adverse event ( Table 4 ). The most common adverse events were neurologic, followed by gastrointestinal complaints. Cardiovascular and psychiatric side effects were the third most common. Importantly, none of the adverse events were life-threatening with 64.7% 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 that were brief and self-resolving as well as 35.5% that resolved after following our adverse events protocol, outlined above. Given the unprecedented COVID-19 pandemic, 14 patients enrolled in the IV ketamine protocol could not proceed with infusions. One of these patients had relief and functional improvement from her last infusion for over three months. The remaining 13 patients reported worsened mobility, function, mood, and/or anorexia. While 78.6% of patients met the definition for response to their last IV ketamine infusion, it is notable that some non-responders had good response when pairing ketamine with acupuncture or deep tissue massages, which they could not proceed with during the pandemic. Due to the return of baseline pain, 61.5% of patients increased their other analgesics including opioids, gabapentinoids, or cannabis to cope. Although not a true crossover analysis, these insights propose that IV ketamine may be an integral part of CNP treatment that patients rely on to maintain their function and mobility as well as decrease their adjuvant analgesics. However, further prospective cross-over studies may further investigate the use of IV ketamine in CNP treatment. This study has several limitations. Objective outcome measures were inconsistently used, particularly those pertaining to specific neuropathic pain scales (i.e. short form McGill Pain Questionnaire) QOL, functional measures, patient satisfaction, and NPRS scores. Additionally, the sample size is small, though it is the largest study to date. A larger, prospective study that is well-designed with consistent and validated outcome measures is warranted. Ultimately, this would be important and useful as CNP can be debilitating and strenuous on patients' day-to-day function and QOL. Adequate pain control may also be important to minimize caregiver burnout. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 This investigation suggests that IV ketamine at subanesthetic doses may be a viable adjuvant to existing treatments, particularly SNRIs to treat CNP. IV ketamine was especially effective when treating CIPN. Additionally, this data demonstrates that an extended IV ketamine protocol is safe and well-tolerated with minimal adverse events and several patients who had long-term pain relief. Neurologic adverse events were the most common, but rare. Larger, prospective studies must be conducted to further illustrate the effects of IV ketamine on CNP and to explore the different parameters that may help prognosticate a good response to IV ketamine. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 TABLE & FIGURE LEGENDS Table 1 : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Table 2 : Response to IV Ketamine. Pain/adverse event-limited refers to patients who came off of the IV ketamine program despite pain relief due to infusion-related adverse event or subsequent infusions resulting in reduced efficacy. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Table 3 : Page 28 of 38 Official Journal of the American Academy of Pain Medicine Pain Medicine 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Table 4 : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Table 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Table 6 : Follow-up on Enrolled Patients During the COVID-19 Pandemic. Pain medication changes refers to medication changes in the thirteen patients whose pain returned to baseline. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 Neuropathic cancer pain: prevalence, pathophysiology, and management The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community Prevalence of chronic pain with neuropathic characteristics in the general population Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study Identification and treatment of neuropathic pain in patients with cancer. International Association for the Study of Pain Neuropathic pain in cancer Mechanisms of chemotherapyinduced peripheral neuropathy Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists Ketamine for pain management Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care Ketamine as an adjuvant to opioids for cancer pain Ketamine produces effective and longterm pain relief in patients with complex regional pain syndrome type 1 Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain The role of the NMDA receptors and larginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation A review of the role of genetic testing in pain medicine Pain Physician Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy We would like to acknowledge the nursing staff at MSKCC who are part of the MSKCC IV ketamine infusion program. In particular, we would like to acknowledge Patricia Donoghue, Mimi Hailemariam, Kelly Leap, Lacey Ferraro, and Jessica Karanikolos. Furthermore, we would like to acknowledge the nursing team at the MSKCC outpatient same day surgery facility who perform in patient care during the infusion. They are vital to the administering of ketamine, monitoring of pain relief and adverse events, follow-up, and well-being of our patients. The authors declare no conflicts of interest or disclosures for this manuscript. Dr. Gulati's disclosures are listed above.